151 related articles for article (PubMed ID: 11704968)
1. Regulation of pharmacoeconomics and outcomes research.
Radensky P
Value Health; 2001; 4(1):12-5. PubMed ID: 11704968
[No Abstract] [Full Text] [Related]
2. Pharmaceuticals and medical devices: FDA oversight.
Berry MD
Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
[No Abstract] [Full Text] [Related]
3. A defense of the learned intermediary doctrine.
Goetz RB; Growdon KR
Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470
[No Abstract] [Full Text] [Related]
4. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
Thomson Reuters/West
Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841
[No Abstract] [Full Text] [Related]
5. Stoning a dead bird: advertising limits on approved new drugs.
Strobos J
Food Drug Law J; 1995; 50(4):533-51. PubMed ID: 10343018
[No Abstract] [Full Text] [Related]
6. Direct-to-consumer prescription drug advertising.
Terzian TV
Am J Law Med; 1999; 25(1):149-67. PubMed ID: 10207573
[No Abstract] [Full Text] [Related]
7. Over-the-counter sales of statins and other drugs for asymptomatic conditions.
Tinetti ME
N Engl J Med; 2008 Jun; 358(25):2728-32. PubMed ID: 18565867
[No Abstract] [Full Text] [Related]
8. Pharmaceuticals and medical devices: business practices.
Steiner DJ
Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
[No Abstract] [Full Text] [Related]
9. Recent developments in direct consumer advertising of attention disorder stimulants and creating limits to withstand constitutional scrutiny.
Strawn MN
J Contemp Health Law Policy; 2003; 19(2):495-520. PubMed ID: 14748255
[No Abstract] [Full Text] [Related]
10. To inform or persuade? Direct-to-consumer advertising of prescription drugs.
Berndt ER
N Engl J Med; 2005 Jan; 352(4):325-8. PubMed ID: 15673797
[No Abstract] [Full Text] [Related]
11. Major issues in marketing regulation.
Pines WL
Food Drug Law J; 1997; 52(3):297-302. PubMed ID: 10343028
[No Abstract] [Full Text] [Related]
12. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
Chaps NA
Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
[No Abstract] [Full Text] [Related]
13. Bias at the gate?: The pharmaceutical industry's influence on the federally approved drug compendia.
Gabrielsen L
Am J Law Med; 2014; 40(1):141-63. PubMed ID: 24844045
[No Abstract] [Full Text] [Related]
14. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
Berry MD
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449
[No Abstract] [Full Text] [Related]
15. Rules set for dissemination of off-label-use information.
Miller JL
Am J Health Syst Pharm; 1999 Feb; 56(3):204. PubMed ID: 10030500
[No Abstract] [Full Text] [Related]
16. US regulation of pharmaceutical outcomes research.
Burke LB
Value Health; 2001; 4(1):5-7. PubMed ID: 11704971
[No Abstract] [Full Text] [Related]
17. The federal preemption debate in pharmaceutical labeling product liability actions.
Gross JM; Curry JA
Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
[No Abstract] [Full Text] [Related]
18. What drug labels don't tell you.
Consum Rep; 2011 Aug; 76(8):10. PubMed ID: 21770080
[No Abstract] [Full Text] [Related]
19. Caveat doctor.
McCarthy M
Lancet; 1999 Aug; 354(9177):446. PubMed ID: 10465167
[No Abstract] [Full Text] [Related]
20. FDA off-track on off-label drug promotion.
Lancet; 2007 Dec; 370(9604):1976. PubMed ID: 18083382
[No Abstract] [Full Text] [Related]
[Next] [New Search]
